184 related articles for article (PubMed ID: 38315795)
41. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.
Demir IE; Jäger C; Schlitter AM; Konukiewitz B; Stecher L; Schorn S; Tieftrunk E; Scheufele F; Calavrezos L; Schirren R; Esposito I; Weichert W; Friess H; Ceyhan GO
Ann Surg; 2018 Dec; 268(6):1058-1068. PubMed ID: 28692477
[TBL] [Abstract][Full Text] [Related]
42. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.
Kaltenmeier C; Nassour I; Hoehn RS; Khan S; Althans A; Geller DA; Paniccia A; Zureikat A; Tohme S
J Gastrointest Surg; 2021 Sep; 25(9):2307-2316. PubMed ID: 33269460
[TBL] [Abstract][Full Text] [Related]
43. Impact of resection margin status on survival after operation for pancreatic head cancer with extrapancreatic nerve plexus invasion.
Konishi T; Takano S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Hosokawa I; Mishima T; Ohtsuka M
J Surg Oncol; 2022 Nov; 126(6):1038-1047. PubMed ID: 35796724
[TBL] [Abstract][Full Text] [Related]
44. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
45. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
[TBL] [Abstract][Full Text] [Related]
46. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma.
Zhang B; Lee GC; Qadan M; Fong ZV; Mino-Kenudson M; Desphande V; Malleo G; Maggino L; Marchegiani G; Salvia R; Scarpa A; Luchini C; De Gregorio L; Ferrone CR; Warshaw AL; Lillemoe KD; Bassi C; Castillo CF
Ann Surg; 2021 Aug; 274(2):e134-e142. PubMed ID: 31851002
[TBL] [Abstract][Full Text] [Related]
47. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
49. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer.
Leonhardt CS; Pils D; Qadan M; Gustorff C; Sahora K; Klaiber U; Warshaw AL; Prager G; Ferrone CR; Lillemoe KD; Schindl M; Strobel O; Castillo CF; Hank T
Eur J Cancer; 2023 Nov; 193():113293. PubMed ID: 37713740
[TBL] [Abstract][Full Text] [Related]
50. In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients.
Kurlinkus B; Ahola R; Zwart E; Halimi A; Yilmaz BS; Ceyhan GO; Laukkarinen J
Scand J Surg; 2020 Mar; 109(1):11-17. PubMed ID: 32192417
[TBL] [Abstract][Full Text] [Related]
51. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
[TBL] [Abstract][Full Text] [Related]
52. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
[TBL] [Abstract][Full Text] [Related]
53. Prognostic relevance of the posterior resection margin for predicting disease free survival in ampullary adenocarcinoma.
Schneider C; Sodergren MH; Pencavel T; Soggiu F; Bhogal RH; Khan AZ
Surg Oncol; 2020 Dec; 35():211-217. PubMed ID: 32911213
[TBL] [Abstract][Full Text] [Related]
54. Relevance of positive resection margins in ductal pancreatic adenocarcinoma and prognostic factors.
Ocaña J; Sanjuanbenito A; García A; Molina JM; Lisa E; Mendía E; Saavedra C; Lobo E
Cir Esp (Engl Ed); 2020 Feb; 98(2):85-91. PubMed ID: 31395275
[TBL] [Abstract][Full Text] [Related]
55. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.
Tummers WS; Groen JV; Sibinga Mulder BG; Farina-Sarasqueta A; Morreau J; Putter H; van de Velde CJ; Vahrmeijer AL; Bonsing BA; Mieog JS; Swijnenburg RJ
Br J Surg; 2019 Jul; 106(8):1055-1065. PubMed ID: 30883699
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
57. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
[TBL] [Abstract][Full Text] [Related]
58. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
[TBL] [Abstract][Full Text] [Related]
59. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
60. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma.
Crippa S; Pergolini I; Javed AA; Honselmann KC; Weiss MJ; Di Salvo F; Burkhart R; Zamboni G; Belfiori G; Ferrone CR; Rubini C; Yu J; Gasparini G; Qadan M; He J; Lillemoe KD; Castillo CF; Wolfgang CL; Falconi M
Ann Surg; 2022 Aug; 276(2):378-385. PubMed ID: 33086324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
